McKinsey Exec On Generative AI in R&D And Pharmacovigilance, Digital Twins

McKinsey & Company's senior partner Vikas Bhadoria, in this first instalment of a wide-ranging two-part interview with Scrip, outlines a number of use cases to define where pharma currently is and the potential value that can be unlocked as industry adopts new technologies such as generative AI, digital twins and the metaverse.

Pharma Could Realize Significant Value From New Technologies • Source: Shutterstock

New technologies like generative artificial intelligence (Gen AI) and digital-twins could potentially rewire the life sciences sector, with several promising use cases across the molecule-to-market continuum.

Vikas Bhadoria, senior partner, McKinsey & Company

More from Business

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By 

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By 

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By 

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

More from Scrip

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By 

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.